# Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

> **NCT06243354** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sichuan Huiyu Pharmaceutical Co., Ltd** · enrollment: 257 (estimated)

## Conditions studied

- Safety
- Tolerability
- Efficacy

## Interventions

- **DRUG:** Test product: HYP-2090PTSA

## Key facts

- **NCT ID:** NCT06243354
- **Lead sponsor:** Sichuan Huiyu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-04
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 257 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06243354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06243354, "Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06243354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*